NVCR · NovoCure Limited

The thesis

NovoCure Limited's shares closed at $14.62 on 27 October 2026, 26.9% below the 52-week high of $19.99, and the third-quarter report due 29 October 2026 before the US market opens settles whether July's improvement was durable. A raise above the $710–725 million full-year revenue outlook and positive adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) would support the case. Unchanged guidance or nonpositive adjusted EBITDA would not.

The measured foundation is still the 23 July 2026 second-quarter report. Revenue was $183.584 million, up 16% from a year earlier. Management lifted the full-year range from $690–710 million to $710–725 million, and adjusted EBITDA was $10.8 million (company release, 23 July 2026). Benzinga reported the shares up 27.7% to $19.88 intraday that day.

Since the 14 October 2026 close of $13.84, the shares have recovered to $14.62. The 14-day Relative Strength Index (RSI), a momentum gauge where readings near 20 mark heavy selling, has moved from 21.9 on 14 October 2026 to 49.7 on 27 October 2026. The shares are down 4.0% over three months.

The narrative is maturing: the July results are three months old, and the only company items since are the 1 September 2026 Cybersecurity disclosure and the 1 October 2026 Japanese approval of Optune Pax, neither with a reported revenue figure. Benzinga's 24 July headline, "Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding," describes the pattern the report now has to break.

Bullish and bearish views on NovoCure Limited

The bull case on NovoCure Limited (NVCR), in brief: Guidance sets a clear test. The bear case: Profit includes one-time items.

Bull case

• Guidance sets a clear test. Management raised the revenue range on 23 July 2026 against a consensus estimate of $708.743 million (Benzinga). A second raise on 29 October 2026 would extend the July step.
• Patient growth underpins revenue. NovoCure reported 5,128 active Tumor Treating Fields (TTFields) patients at 30 June 2026, against 4,331 a year earlier (company release, 23 July 2026). Third-quarter 2025 revenue was $167.2 million, up 8%, with 4,416 active patients at 30 September 2025, which sets the comparison for this report.
• Pancreatic label keeps widening. Japan's Ministry of Health, Labour and Welfare approved Optune Pax on 1 October 2026 for unresectable locally advanced pancreatic cancer, with gemcitabine and nab-paclitaxel. A European CE mark followed on 30 June 2026.
• Trial evidence supports the label. In the PANOVA-3 trial, median overall survival rose from 14.2 to 16.2 months with TTFields plus chemotherapy (OncLive, 1 October 2026).
• Some analysts remain constructive. Analyst Jason Bednar maintained a Buy rating on 27 October 2026, and HC Wainwright's target is $52 (23 July 2026). Benzinga's snapshot shows four Buy and two Hold ratings among six analysts and an average target of $27.

Bear case

• Profit includes one-time items. The 23 July 2026 release disclosed $2.8 million of one-time revenue benefits and a $4.9 million tariff refund. Adjusted EBITDA of $10.8 million sits close to the combined size of those items.
• Reported losses remain large. The first-half 2026 net loss was $86.8 million and the accumulated deficit was $1,377.2 million (second-quarter filing, 30 June 2026).
• The company said it does not expect a material financial impact and would amend its 8-K under Item 1.05 within four business days if that changed.
• The market has not paid for the beat. The shares gave back the July gain through September and October despite the raised outlook, closing at $14.62 on 27 October 2026 against the $19.88 intraday July peak.
• Targets sit near the price. JP Morgan (Neutral, $17, 13 July 2026), Wells Fargo ($17) and Wedbush (Neutral, $20, 24 July 2026) cluster not far above the last close. The $52 Buy target is an outlier.

Price setup

The adjusted close on 27 October 2026 was $14.62. The 52-week high is $19.99, and the 23 July intraday peak was $19.88. Adjusted closes fell from $17.94 on 4 September 2026 to $16.69 on 18 September 2026, $15.92 on 1 October 2026 and $13.84 on 14 October 2026 before the recent recovery.

The $12.50 invalidation level sits below the 14 October 2026 close of $13.84, the lowest close cited here. With earnings the next day, the price range around the report is wide, and a move in either direction is possible on the first session after the release.

Crowding evidence is limited. The earnings date is imminent, and no heavy retail attention, share issuance or insider selling is reported in company news. Sell-side targets span about 3x, from $17 to $52, which shows analysts disagree on value. The sample of public items since mid-October is too small to read a change in positioning.

Catalysts, next 30 days

• Any time — Amended 8-K under Item 1.05, required within four business days if the Cybersecurity incident is judged material.

Elapsed catalysts

• 29 October 2026 — Third-quarter 2026 results, before the US market opens, with a call at 8:00 a.m. Eastern. This settles revenue guidance, adjusted EBITDA and patient growth against the 30 June 2026 figure of 5,128. (passed 8d ago)
• ~29 October to 5 November 2026, est. Quarterly filing (Form 10-Q). It would show net loss, cash and any quantified cost of the September Cybersecurity incident. (passed 1d ago)

What would change the view

The case breaks if the 29 October 2026 report leaves the $710–725 million revenue outlook unchanged or lower, or shows adjusted EBITDA at or below zero. Either result would suggest the second quarter leaned on its $2.8 million of one-time revenue and $4.9 million tariff refund. A quantified cost from the Cybersecurity incident, or an amended 8-K under Item 1.05, would add a second reason.

On price, a daily close below $12.50 would extend the slide below the 14 October 2026 close and mean the market rejects the July improvement. A raise to guidance with positive adjusted EBITDA and growth in active patients above 5,128 would move the case toward confirmation.

What it trades with

TTFields is a category of one: no listed peer sells a comparable device, so no sector cohort confirms or refutes a move in the shares. The stock has traded on its own company news, with the largest single-day move on the 23 July 2026 report, when it rose 27.7% intraday while the Nasdaq fell 2.03% (Benzinga). Broad-market direction on 29 October 2026 is therefore a weaker driver than the company's own numbers.